NYSE American - Delayed Quote • USD
IGC Pharma, Inc. (IGC)
At close: April 18 at 4:00 PM EDT
After hours: April 18 at 7:58 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -0.04 | -0.04 | -0.22 | -0.16 |
| Low Estimate | -0.04 | -0.04 | -0.22 | -0.16 |
| High Estimate | -0.04 | -0.04 | -0.22 | -0.16 |
| Year Ago EPS | -- | -- | -- | -0.22 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | 190k | 620k | 1.24M | 1.4M |
| Low Estimate | 190k | 620k | 1.24M | 1.4M |
| High Estimate | 190k | 620k | 1.24M | 1.4M |
| Year Ago Sales | -- | -- | -- | 1.24M |
| Sales Growth (year/est) | -- | -- | -- | 12.90% |
Earnings History
| CURRENCY IN USD | ||||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | -- |
| EPS Actual | -- | -- | -- | -- |
| Difference | -- | -- | -- | -- |
| Surprise % | -- | -- | -- | -- |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.04 | -0.04 | -0.22 | -0.16 |
| 7 Days Ago | -0.04 | -0.04 | -0.22 | -0.16 |
| 30 Days Ago | -0.04 | -0.04 | -0.22 | -0.16 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | IGC | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 0.80% |
| Next Qtr. | -- | -- | -- | 9.60% |
| Current Year | -- | -- | -- | 4.50% |
| Next Year | 27.30% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Related Tickers
ATHE Alterity Therapeutics Limited
2.1400
+3.38%
GRTX Galera Therapeutics, Inc.
0.1860
-6.25%
SNGX Soligenix, Inc.
0.4353
-14.65%
ALLR Allarity Therapeutics, Inc.
1.5400
+2.67%
CLNN Clene Inc.
0.3299
-2.86%
BRTX BioRestorative Therapies, Inc.
1.4400
+3.60%
PXMD PaxMedica, Inc.
0.7631
-4.60%
SPRC SciSparc Ltd.
1.2900
-2.27%
ONVO Organovo Holdings, Inc.
1.1500
+2.68%
PALI Palisade Bio, Inc.
5.07
-23.18%